Wout De Wispelaere, Daniela Annibali, Sandra Tuyaerts, Julie Messiaen, Asier Antoranz, Gautam Shankar, Nikolina Dubroja, Alejandro Herreros-Pomares, Regina E M Baiden-Amissah, Marie-Pauline Orban, Marcello Delfini, Emanuele Berardi, Thomas Van Brussel, Rogier Schepers, Gino Philips, Bram Boeckx, Maria Francesca Baietti, Luigi Congedo, Kiave Yune HoWangYin, Emilie Bayon, Anne-Sophie Van Rompuy, Eleonora Leucci, Sebastien P Tabruyn, Francesca Bosisio, Massimiliano Mazzone, Diether Lambrechts, Frédéric Amant
BACKGROUND: Uterine leiomyosarcomas (uLMS) are aggressive tumours with poor prognosis and limited treatment options. Although immune checkpoint blockade (ICB) has proven effective in some 'challenging-to-treat' cancers, clinical trials showed that uLMS do not respond to ICB. Emerging evidence suggests that aberrant PI3K/mTOR signalling can drive resistance to ICB. We therefore explored the relevance of the PI3K/mTOR pathway for ICB treatment in uLMS and explored pharmacological inhibition of this pathway to sensitise these tumours to ICB...
May 2024: Clinical and Translational Medicine